Cargando…

Pemafibrate decreases markers of hepatic inflammation in patients with non-alcoholic fatty liver disease

AIM OF THE STUDY: Non-alcoholic fatty liver disease (NAFLD) is frequently complicated by dyslipidemia and is considered to be a hepatic manifestation of metabolic syndrome. Pemafibrate is a novel selective peroxisome proliferator-activated receptor-α modulator. There are no reports of the clinical e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shinozaki, Satoshi, Tahara, Toshiyuki, Lefor, Alan Kawarai, Ogura, Masahito
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2020
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592096/ https://www.ncbi.nlm.nih.gov/pubmed/33145434 http://dx.doi.org/10.5114/ceh.2020.99528

Ejemplares similares

Pemafibrate improves hepatic inflammation, function and fibrosis in patients with non-alcoholic fatty liver disease: a one-year observational study
por: Shinozaki, Satoshi, et al.
Publicado: (2021)

Pemafibrate therapy for non-alcoholic fatty liver disease is more effective in lean patients than obese patients
por: Shinozaki, Satoshi, et al.
Publicado: (2022)

Effectiveness of One-Year Pemafibrate Therapy on Non-Alcoholic Fatty Liver Disease Refractory to Long-Term Sodium Glucose Cotransporter-2 Inhibitor Therapy: A Pilot Study
por: Shinozaki, Satoshi, et al.
Publicado: (2023)

Effect of pemafibrate on liver enzymes and shear wave velocity in non-alcoholic fatty liver disease patients
por: Sugimoto, Ryosuke, et al.
Publicado: (2023)

Normalization of Flow in the Common Hepatic Artery after Decompression of Median Arcuate Ligament Syndrome with Diminution of a Pancreatoduodenal Arcade Aneurysm
por: Matsumoto, Kenji, et al.
Publicado: (2022)

Effect of 48‐week pemafibrate on non‐alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan‐aspartate aminotransferase score
por: Hatanaka, Takeshi, et al.
Publicado: (2021)

Effects of body composition and liver function after long-term pemafibrate treatment on dyslipidemia-associated non-alcoholic fatty liver disease
por: Ishikawa, Toru, et al.
Publicado: (2023)

Nonsurgical rescue after basket-stone impaction by endoscopic cutting of a metallic lithotripter and laser lithotripsy
por: Terauchi, Toshiaki, et al.
Publicado: (2021)

Combination Therapy Using Pemafibrate and Dapagliflozin for Metabolic Dysfunction-associated Fatty Liver Disease
por: Imamura, Teruhiko, et al.
Publicado: (2022)

Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study
por: Morishita, Asahiro, et al.
Publicado: (2022)

Pemafibrate Ameliorates Liver Dysfunction and Fatty Liver in Patients with Non-Alcoholic Fatty Liver Disease with Hypertriglyceridemia: A Retrospective Study with the Outcome after a Mid-Term Follow-Up
por: Ikeda, Suguru, et al.
Publicado: (2021)

An Ultrathin Endoscope with a 2.4-mm Working Channel Shortens the Esophagogastroduodenoscopy Time by Shortening the Suction Time
por: Shinozaki, Satoshi, et al.
Publicado: (2015)

An Ultrathin Endoscope with a 2.4-mm Working Channel Shortens the Esophagogastroduodenoscopy Time by Shortening the Suction Time
por: Shinozaki, Satoshi, et al.
Publicado: (2016)

Roles of Capsule Endoscopy and Balloon-Assisted Enteroscopy in the Optimal Management of Small Bowel Bleeding
por: Abutalib, Hani, et al.
Publicado: (2020)

Linked color imaging for the detection of early gastrointestinal neoplasms
por: Shinozaki, Satoshi, et al.
Publicado: (2019)

The Pocket-Creation Method Facilitates Endoscopic Submucosal Dissection of Gastric Neoplasms Along the Lesser Curvature at the Gastric Angle
por: Kitamura, Masafumi, et al.
Publicado: (2022)

Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis †
por: Yamashita, Shizuya, et al.
Publicado: (2023)

Presence of Fatty Liver and the Relationship between Alcohol Consumption and Markers of Inflammation
por: Kächele, Martin, et al.
Publicado: (2015)

Pemafibrate Protects against Fatty Acid-Induced Nephropathy by Maintaining Renal Fatty Acid Metabolism
por: Aomura, Daiki, et al.
Publicado: (2021)

Impact of Pemafibrate in Patients with Hypertriglyceridemia and Metabolic Dysfunction-associated Fatty Liver Disease Pathologically Diagnosed with Non-alcoholic Steatohepatitis: A Retrospective, Single-arm Study
por: Hatanaka, Takeshi, et al.
Publicado: (2021)

Effectiveness and safety of endoscopic submucosal dissection using the pocket creation method in the Japanese population: a systematic review and meta-analysis
por: Shinozaki, Satoshi, et al.
Publicado: (2022)

Laparoscopic and Robot-Assisted Hepatic Surgery: An Historical Review
por: Shimizu, Atsushi, et al.
Publicado: (2022)

Cystic Pancreatic Neuroendocrine Tumor in a Patient with Neurofibromatosis Type 1
por: Shinozaki, Hiroharu, et al.
Publicado: (2021)

Cholangiocarcinoma Presenting after Eight Years of Treatment of IgG4-Related Autoimmune Pancreatitis with Steroids
por: Shinozaki, Hiroharu, et al.
Publicado: (2021)

A Significant Effect of Pemafibrate on Hepatic Steatosis and Fibrosis Indexes in Patients With Hypertriglyceridemia
por: Katsuyama, Hisayuki, et al.
Publicado: (2023)

Pemafibrate, a selective PPARα modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content
por: Sasaki, Yusuke, et al.
Publicado: (2020)

Extended cold snare polypectomy for small colorectal polyps increases the R0 resection rate
por: Abe, Yasuhiro, et al.
Publicado: (2018)

Intussusception due to an Inverted Meckel's Diverticulum Diagnosed by Double-Balloon Enteroscopy
por: Kawasaki, Yuki, et al.
Publicado: (2017)

Advanced Treatment and Imaging in Colonoscopy: The Pocket-Creation Method for Complete Resection and Linked Color Imaging for Better Detection of Early Neoplastic Lesions by Colonoscopy
por: Yamamoto, Hironori, et al.
Publicado: (2019)

Development of a gel dedicated to gel immersion endoscopy
por: Yano, Tomonori, et al.
Publicado: (2021)

Antithrombotic drugs do not increase intraoperative blood loss in emergency gastrointestinal surgery: a single-institution propensity score analysis
por: Matsuoka, Tadashi, et al.
Publicado: (2019)

Single-Stage Endoscopic Stone Extraction and Cholecystectomy during the Same Hospitalization
por: Terauchi, Toshiaki, et al.
Publicado: (2019)

The Sasaki-W anastomosis for recurrent Crohn’s disease stenosis after the Kono-S anastomosis
por: Asai, Takahiro, et al.
Publicado: (2023)

Inflammation and fibrosis in chronic liver diseases including non-alcoholic fatty liver disease and hepatitis C
por: Tanwar, Sudeep, et al.
Publicado: (2020)

Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease
por: Nakajima, Atsushi, et al.
Publicado: (2021)

Relationship between non-alcoholic fatty liver disease and inflammation in patients with non-alcoholic fatty liver
por: Foroughi, Mehdi, et al.
Publicado: (2016)

Laparoscopic resection of sigmoid colon cancer with intestinal malrotation: A case report
por: Nishida, Kazuhiro, et al.
Publicado: (2017)

Pemafibrate Prevents Rupture of Angiotensin II-Induced Abdominal Aortic Aneurysms
por: Amioka, Naofumi, et al.
Publicado: (2022)

Markers of Inflammation and Fibrosis in Alcoholic Hepatitis and Viral Hepatitis C
por: Neuman, Manuela G., et al.
Publicado: (2012)

Preferable effects of pemafibrate on liver function and fibrosis in subjects with type 2 diabetes complicated with liver damage
por: Nomoto, Hiroshi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_t9rlu8dskmmpi4mtn2hlvjckbj